Drugs / DREAM01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07432867 | Feb 2026 → Feb 2032 expected | sickle cell disease | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DREAM01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07432867 ↗ |
| Modality | Cell therapy | “DREAM01 is a genetically modified cell therapy product” NCT07432867 ↗ |
| Route | Intravenous | “single IV infusion” NCT07432867 ↗ |